AstraZeneca seeks to move past China probe with Beijing R&D hub
HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual stance in its second-biggest market.
The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...
New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as ...
The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...
AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here ...
New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) ...
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...
LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) announced that new study results presented at the European Lung Cancer Congress (ELCC) 2025, demonstrated the role of the company's TAGRISSO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback